Table of Contents

State/Territory Name: Massachusetts

State Plan Amendment (SPA) #: 21-0013

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS-179
- 3) Approved SPA Pages



Medicaid and CHIP Operations Group

November 12, 2021

MaryLou Sudders, Secretary The Commonwealth of Massachusetts Executive Office of Health and Human Services Office of Medicaid One Ashburton Place, Room 1109 Boston, MA 02108

Re: Massachusetts State Plan Amendment (SPA) 21-0013

Dear Secreatry Sudders:

The Centers for Medicare & Medicaid Services (CMS) reviewed your Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) 21-0013. This amendment proposes to add medication-assisted treatment (MAT) as a mandatory benefit in the Medicaid state plan. This letter is to inform you that Connecticut's Medicaid SPA Transmittal Number 21-0013 is approved effective October 1, 2020 until September 30, 2025, pursuant to 1905(a)(29) of the Social Security Act and Section 1006(b) of the SUPPORT Act.

Section 1006(b) of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act ("SUPPORT Act"), signed into law on October 24, 2018, amended section 1902(a)(10)(A) of the Social Security Act (the Act) to require state Medicaid plans to include coverage of MAT for all individuals eligible to enroll in the state plan or waiver of the state plan. Section 1006(b) also added a new paragraph 1905(a)(29) to the Act to include the new required benefit in the definition of "medical assistance" and to specify that the new required benefit will be in effect for the period beginning October 1, 2020, and ending September 30, 2025.

Section 1006(b) of the SUPPORT Act also added section 1905(ee)(1) to the Act to define MAT, for purposes of the new required coverage, as:

... all drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), including methadone, and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262) to treat opioid use disorders; and[,] ... with respect to the provision of such drugs and biological products, counseling services and behavioral therapy.

Pursuant to section 1135(b)(5) and/or 1135(b)(1)(C) of the Act, due to the COVID-19 public health emergency (PHE), CMS issued an approval letter on March 12, 2021 allowing

Page 2

Massachusetts to modify the SPA submission requirements at 42 C.F.R. 430.20, to allow the state to submit a SPA implementing section 1905(a)(29) of the Act by March 31, 2021 that would take effect on October 1, 2020 and was approved November 10, 2021.

CMS conducted our review of your submittal according to statutory requirements in Title XIX of the Act and implementing regulations.

If you have any questions, please contact Marie DiMartino 617-565-9157 or via email at Marie.DiMartino@cms.hhs.gov.

Sincerely,



James G. Scott, Director Division of Program Operations

DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES	FORM APPROVED OMB No. 0938-0193	
	1. TRANSMITTAL NUMBER 2. STATE	
TRANSMITTAL AND NOTICE OF APPROVAL OF	21 - 01 - 3 MA	
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	SECURITY ACT (MEDICAID)	
TO: REGIONALADMINISTRATOR	4. PROPOSED EFFECTIVE DATE	
CENTERS FOR MEDICARE & MEDICAID SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	10/01/20	
5. TYPE OF PLAN MATERIAL (Check One)		
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AME	NDMENT (Separate transmittal for each amendment)	
6. FEDERAL STATUTE/REGULATION CITATION	7. FEDERAL BUDGET IMPACT	
42 USC 1396a(a)(13); 42 CFR Part 447; 42 CFR 440.10	a. FFY21\$0 b. FFY22\$0	
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable)	
Supplement to Attachment 3.1-A page 3a9 (NEW) Supplement to Attachment 3.1-B page 3a9 (NEW) Attachment 4.19-B page 1r (NEW)		
10. SUBJECT OF AMENDMENT		
Medication Assisted Treatment (MAT) Benefit		
11. GOVERNOR'S REVIEW (Check One)		
GOVERNOR'S OFFICE REPORTED NO COMMENT	OTHER, AS SPECIFIED	
 COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL 	Not required under 42 CFR 430.12(b)(2)(i)	
	16. RETURN TO	
13. TYPED NAME	The Commonwealth of Massachusetts	
Marylou Sudders	Executive Office of Health and Human Services	
14. TITLE Secretary	Office of Medicaid One Ashburton Place, Room 1 109 Boston, MA 02108	
15. DATE SUBMITTED		
03/31/21		
	OFFICE USE ONLY	
17. DATE RECEIVED 03/31/21	18. DATE APPROVED 11/10/21	
	DNE COPY ATTACHED	
19. EFFECTIVE DATE OF APPROVED MATERIAL		
10/1/20		
21. TYPED NAME	22. TITLE Director	
James G. Scott	Division of Program Operations	
23. REMARKS		

1905(a)(29) Medication-Assisted Treatment (MAT)

Citation: 3.1(a)(1) Amount, Duration, and Scope of Services: Categorically Needy (Continued)

1905(a)(29) __x__MAT as described and limited in Supplement __0__ to Attachment 3.1-A.

ATTACHMENT 3.1-A identifies the medical and remedial services provided to the categorically needy.

1905(a)(29) Medication-Assisted Treatment (MAT)

Amount, Duration, and Scope of Medical and Remedial Care Services Provided to the Categorically Needy (continued)

i. General Assurance

MAT is covered under the Medicaid state plan for all Medicaid beneficiaries who meet the medical necessity criteria for receipt of the service for the period beginning October 1, 2020, and ending September 30, 2025.

- ii. Assurances
 - a. The state assures coverage of Naltrexone, Buprenorphine, and Methadone and all of the forms of these drugs for MAT that are approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262).
 - b. The state assures that Methadone for MAT is provided by Opioid Treatment Programs that meet the requirements in 42 C.F.R. Part 8.
 - c. The state assures coverage of all current and future formulations of drugs prescribed or administered for MAT that are approved for the treatment of OUD under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all current and future formulations of biological drugs prescribed or administered for MAT that are licensed for the treatment of OUD under section 351 of the Public Health Service Act (42 U.S.C. 262), including all formulations of Naltrexone, Buprenorphine, and Methadone prescribed or administered for MAT.

iii. Service Package

The state covers the following counseling services and behavioral health therapies as part of MAT.

a) Please set forth each service and components of each service (if applicable), along with a description of each service and component service.

From October 1, 2020, through September 30, 2025, the state assures that MAT to treat OUD as defined at section 1905(ee)(1) of the Social Security Act (the Act) is covered exclusively under section 1905(a)(29) of the Act.Members have access to the following counseling services and behavioral health therapies as a part of MAT:

<u>Medication Administration</u> – Medication administration through opioid treatment program includes medical assessment and dispensing of medication to opiate-addicted individuals who require support of MAT.

<u>Biopsychosocial Assessment</u> - A comprehensive, diagnostic assessment of presenting problem, medical and behavioral health conditions, social functioning and determinants of health that results in recommendations for treatment. Service requires active involvement of beneficiary.

<u>Family Counseling</u> — Therapeutic counseling of more than one member of a family at the same time in the same session, where the primary complaint or concern is disruption of the family due to opioid use disorder. Family Counseling may involve the participation of a non-Medicaid eligible for the direct benefit of the beneficiary. The service must actively involve the beneficiary in the sense of being tailored to the beneficiary's individual needs. There may be times when, based on clinical judgment, the beneficiary is not present during the delivery of the service, but remains the focus of the service.

<u>Group Counseling</u> — Therapeutic counseling to an unrelated group of people having a common problem or concern that is associated with opioid use disorder.

<u>Individual Counseling</u> — A therapeutic meeting between the staff of an eligible provider and an individual whose primary complaint or concern is his or her opioid use disorder or that of a significant other. Individual counseling includes diagnostic evaluation and assessment, treatment plan development psychotherapy for crisis, and care coordination. Individual Counseling may involve the participation of a non-Medicaid eligible for the direct benefit of the beneficiary. The service must actively involve the beneficiary in the sense of being tailored to the beneficiary's individual needs. There may be times when, based on clinical judgment, the beneficiary is not present during the delivery of the service, but remains the focus of the service.

b) Please include each practitioner and provider entity that furnishes each service and component service.

Please refer to iii.c below.

c) Please include a brief summary of the qualifications for each practitioner or provider entity that the state requires. Include any licensure, certification, registration, education, experience, training and supervisory arrangements that the state requires.

Opioid Treatment Programs must be licensed by the Bureau of Substance Addiction Services, and practice in accordance with the terms of licensure for Substance Abuse Treatment programs through the Massachusetts Department of Public Health.

Practitioners within opioid treatment programs, requirements, and coverable services can be found below:

Provider/Practitioner	License/Certification/Requirements	Coverable MAT Related Services
Physician	Working within scope of practice under state law	Medication Administration
Physician Assistant	Working within scope of practice under state law	Medication Administration
APRN	Working within scope of practice under state law	Medication Administration

Registered Nurse or Practical Nurse	Working within scope of practice under state law	Medication Administration
Licensed Independent Clinical Social Worker Licensed Clinical Social Worker	Working within scope of practice under state law	Family Counseling Group Counseling Individual Counseling Biopsychosocial Assessment
Licensed Mental Health Counselor	Working within scope of practice under state law	Family Counseling Group Counseling Individual Counseling Biopsychosocial Assessment
Licensed Alcohol and Drug Counselor	Working within scope of practice under state law LADC II and LADC III are supervised by LADC I or other independently licensed practitioner	Family Counseling Group Counseling Individual Counseling Biopsychosocial Assessment
Masters Level Clinicians Working Towards Licensure	Supervision by independently licensed practitioner. This practitioner type must hold a Master's Degree in social work, psychology, counseling or a related field. Clinicians must be pursuing independent licensure as a social worker, psychologist, mental health counselor, and/or addictions counselor.	Family Counseling Group Counseling Individual Counseling Biopsychosocial Assessment

iv. Utilization Controls

 $X_{\text{The state has drug utilization controls in place. (Check each of the following that apply)}$

X Generic first policy X Preferred drug lists X Clinical criteria X Quantity limits

____ The state does not have drug utilization controls in place.

v. Limitations

Describe the state's limitations on amount, duration, and scope of MAT drugs, biologicals, and counseling and behavioral therapies related to MAT.

Limitations on amount, duration, and scope are based on clinical necessity. The state has a generic first policy, but may prefer a brand-name drug based on net cost information.

PRA Disclosure Statement - This information is being collected to assist the Centers for Medicare & Medicaid Services in implementing section 1006(b) of the SUPPORT for Patients and Communities Act (P.L. 115-271) enacted on October 24, 2018. Section 1006(b) requires state Medicaid plans to provide coverage of Medication-Assisted Treatment (MAT) for all Medicaid enrollees as a mandatory Medicaid state plan benefit for the period beginning October 1, 2020, and ending September 30, 2025. Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 60). Public burden for all of the collection of information requirements under this control number is estimated to take about 80 hours per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

1905(a)(29) Medication-Assisted Treatment (MAT)

Citation: 3.1(a)(1) Amount, Duration, and Scope of Services: Categorically Needy (Continued)

1905(a)(29) __x__MAT as described and limited in Supplement __0__ to Attachment 3.1-A.

ATTACHMENT 3.1-A identifies the medical and remedial services provided to the categorically needy.

1905(a)(29) Medication-Assisted Treatment (MAT)

Amount, Duration, and Scope of Medical and Remedial Care Services Provided to the Categorically Needy (continued)

i. General Assurance

MAT is covered under the Medicaid state plan for all Medicaid beneficiaries who meet the medical necessity criteria for receipt of the service for the period beginning October 1, 2020, and ending September 30, 2025.

- ii. Assurances
 - a. The state assures coverage of Naltrexone, Buprenorphine, and Methadone and all of the forms of these drugs for MAT that are approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262).
 - b. The state assures that Methadone for MAT is provided by Opioid Treatment Programs that meet the requirements in 42 C.F.R. Part 8.
 - c. The state assures coverage of all current and future formulations of drugs prescribed or administered for MAT that are approved for the treatment of OUD under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all current and future formulations of biological drugs prescribed or administered for MAT that are licensed for the treatment of OUD under section 351 of the Public Health Service Act (42 U.S.C. 262), including all formulations of Naltrexone, Buprenorphine, and Methadone prescribed or administered for MAT.

iii. Service Package

The state covers the following counseling services and behavioral health therapies as part of MAT.

a) Please set forth each service and components of each service (if applicable), along with a description of each service and component service.

From October 1, 2020, through September 30, 2025, the state assures that MAT to treat OUD as defined at section 1905(ee)(1) of the Social Security Act (the Act) is covered exclusively under section 1905(a)(29) of the Act.Members have access to the following counseling services and behavioral health therapies as a part of MAT:

<u>Medication Administration</u> – Medication administration through opioid treatment program includes medical assessment and dispensing of medication to opiate-addicted individuals who require support of MAT.

<u>Biopsychosocial Assessment</u> - A comprehensive, diagnostic assessment of presenting problem, medical and behavioral health conditions, social functioning and determinants of health that results in recommendations for treatment. Service requires active involvement of beneficiary.

<u>Family Counseling</u> — Therapeutic counseling of more than one member of a family at the same time in the same session, where the primary complaint or concern is disruption of the family due to opioid use disorder. Family Counseling may involve the participation of a non-Medicaid eligible for the direct benefit of the beneficiary. The service must actively involve the beneficiary in the sense of being tailored to the beneficiary's individual needs. There may be times when, based on clinical judgment, the beneficiary is not present during the delivery of the service, but remains the focus of the service.

<u>Group Counseling</u> — Therapeutic counseling to an unrelated group of people having a common problem or concern that is associated with opioid use disorder.

<u>Individual Counseling</u> — A therapeutic meeting between the staff of an eligible provider and an individual whose primary complaint or concern is his or her opioid use disorder or that of a significant other. Individual counseling includes diagnostic evaluation and assessment, treatment plan development psychotherapy for crisis, and care coordination. Individual Counseling may involve the participation of a non-Medicaid eligible for the direct benefit of the beneficiary. The service must actively involve the beneficiary in the sense of being tailored to the beneficiary's individual needs. There may be times when, based on clinical judgment, the beneficiary is not present during the delivery of the service, but remains the focus of the service.

b) Please include each practitioner and provider entity that furnishes each service and component service.

Please refer to iii.c below.

c) Please include a brief summary of the qualifications for each practitioner or provider entity that the state requires. Include any licensure, certification, registration, education, experience, training and supervisory arrangements that the state requires.

Opioid Treatment Programs must be licensed by the Bureau of Substance Addiction Services, and practice in accordance with the terms of licensure for Substance Abuse Treatment programs through the Massachusetts Department of Public Health..

Practitioners within opioid treatment programs, requirements, and coverable services can be found below:

Provider/Practitioner	License/Certification/Requirements	Coverable MAT Related
		Services
Physician	Working within scope of practice under state law	Medication Administration

e Medication Administration
e Medication Administration
e Medication Administration
e Family Counseling Group Counseling Individual Counseling Biopsychosocial Assessment
ee Family Counseling Group Counseling Individual Counseling Biopsychosocial Assessment
re Family Counseling Group Counseling Individual Counseling Biopsychosocial Assessment ner
Family Counseling Group Counseling Individual Counseling Biopsychosocial Assessment
-

iv. Utilization Controls

 X_{max} The state has drug utilization controls in place. (Check each of the following that apply)

X Generic first policy X Preferred drug lists X Clinical criteria X Quantity limits

The state does not have drug utilization controls in place.

v. Limitations

Describe the state's limitations on amount, duration, and scope of MAT drugs, biologicals, and counseling and behavioral therapies related to MAT.

Limitations on amount, duration, and scope are based on clinical necessity. The state has a generic first policy, but may prefer a brand-name drug based on net cost information.

PRA Disclosure Statement - This information is being collected to assist the Centers for Medicare & Medicaid Services in implementing section 1006(b) of the SUPPORT for Patients and Communities Act (P.L. 115-271) enacted on October 24, 2018. Section 1006(b) requires state Medicaid plans to provide coverage of Medication-Assisted Treatment (MAT) for all Medicaid enrollees as a mandatory Medicaid state plan benefit for the period beginning October 1, 2020, and ending September 30, 2025. Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 60). Public burden for all of the collection of information requirements under this control number is estimated to take about 80 hours per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

1905(a)(29) Medication-Assisted Treatment (MAT)

Unbundled prescribed drugs for MAT shall be reimbursed using the same methodology as described in Attachment 4.19-B, for covered outpatient drug reimbursement in sections 8.h. and 8.l. for prescribed drugs that are dispensed or administered.

Counseling services and behavioral therapy for MAT shall be reimbursed using the same methodology as described in Attachment 4.19-B, for covered substance use disorder treatment clinics services reimbursement section 8.h.